Aktis Oncology, Inc.
Aktis Oncology, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|
Common Stock | 53 | |||||
Assets | ||||||
Assets Current | ||||||
Cash And Cash Equivalents At Carrying Value | 372 | |||||
Marketable Securities | 167 | |||||
Prepaid Expense And Other Assets Current | 5 | |||||
Assets Current | 544 | |||||
Property Plant And Equipment Net | 15 | |||||
Operating Lease Right Of Use Asset | 13 | |||||
Restricted Cash Equivalents Noncurrent | 1 | |||||
Other Assets | 4 | |||||
Assets | 577 | |||||
Liabilities And Stockhold… | ||||||
Liabilities Current | ||||||
Accounts Payable Current | 1 | |||||
Accrued Liabilities Current | 6 | |||||
Deferred Revenue Current | 19 | |||||
Operating Lease Liability Current | 1 | |||||
Liabilities Current | 28 | |||||
Deferred Revenue Noncurrent | 33 | |||||
Operating Lease Liability Noncurrent | 10 | |||||
Liabilities | 71 | |||||
Stockholders Equity Inclu… | ||||||
Stockholders Equity | ||||||
Additional Paid In Capital Common Stock | 681 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -0 | |||||
Retained Earnings Accumulated Deficit | -175 | |||||
Stockholders Equity | 506 | |||||
Liabilities And Stockholders Equity | 577 | |||||
Series Seed Redeemable Convertible Preferred Stock | 0 | |||||
Series A Redeemable Convertible Preferred Stock | 0 | |||||
Series B Redeemable Convertible Preferred Stock | 0 | |||||
Partner Redeemable Convertible Preferred Stock | 0 | |||||
Common Class A | 0 | |||||
Common Stock No Par Value | 0 | |||||
Common Stock Shares Authorized | 480 | |||||
Common Stock Shares Issued | 53 | |||||
Shares Outstanding | 53 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month |
|---|---|---|---|
| 2026 | 3.28% | 73.84% | - |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | |||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Aktis Oncology, Inc. (AKTS) — SEC Financial Statements & Analysis
Aktis Oncology, Inc. (AKTS) is a pharmaceutical preparations company, incorporated in DE. Aktis Oncology, Inc. trades on Nasdaq as: AKTS. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Aktis Oncology, Inc. reported a Debt-to-Equity ratio of 0.14x, a Price-to-Book (P/B) ratio of 1.72 (TTM), at a market cap of $869.99M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.14x
- P/B TTM
- 1.72
- Market Cap
- $869.99M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aktis Oncology, Inc. in?
Aktis Oncology, Inc. (AKTS) operates in the Pharmaceutical Preparations industry.
What is AKTS's market cap?
Aktis Oncology, Inc. (AKTS) has a market capitalization of $869.99M as of 2026-03-31.
What exchange does AKTS trade on?
Aktis Oncology, Inc. (AKTS) trades on the Nasdaq.
Where is Aktis Oncology, Inc. incorporated?
Aktis Oncology, Inc. is incorporated in DE.